The global oligonucleotide synthesis market is gaining prominent momentum in 2025 as the biotech and therapeutic landscape increasingly pivots toward precision medicine, gene-editing technologies and advanced diagnostics. Oligonucleotides—short, custom DNA or RNA strands—are the foundational “building blocks” enabling antisense therapies, siRNA, aptamers, CRISPR guide RNAs, diagnostic probes and more. As demand for these molecules surges, synthesis capacity, automation, and quality-control standards are rapidly evolving. For device manufacturers, contract development-and-manufacturing organisations (CDMOs), reagent suppliers and biotech firms, this means a strategic inflection point: building capability in oligo synthesis is no longer optional—it’s central to the next generation of therapies and diagnostics.

Latest Developments (2024–2025)

• Automation & AI are increasingly embedded in synthesis workflows: advanced robotics and machine-learning algorithms are being used to optimise synthesis protocols, reduce human error and accelerate throughput for customized oligos.
• There’s notable emphasis on longer and more complex oligonucleotides (beyond typical short primers): for example, DNA Script’s advancements in synthesizing longer custom sequences were highlighted.
• Strategic expansions: Providers are investing in capacity and services to meet increasing demand—especially for therapeutic-grade oligos (GMP, large scale). For example, more than 110 providers claim capabilities to offer oligonucleotide synthesis services globally, with many adding purification services.
• Regional manufacturing is gaining momentum: Asia-Pacific is emerging as a fast-growing region for oligo synthesis due to research funding, biotech expansion and localisation of supply.

These trends reflect how the oligonucleotide synthesis market is moving from a niche tool-set for research labs to a core component of therapeutic- and diagnostic-centric ecosystems.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=200829350

Market Overview & Key Insights

Market Size & Forecast

• The global oligonucleotide synthesis market, valued at US$8.9 billion in 2024, stood at US$10.5 billion in 2025 and is projected to advance at a resilient CAGR of 18.6% from 2025 to 2030, culminating in a forecasted valuation of US$24.7 billion by the end of the period.
• Drivers behind these numbers include increasing demand for therapeutic oligonucleotides (antisense, siRNA), growth in diagnostics and gene-editing platforms, and advances in synthesis technologies.

Key Segments & Players

• By product: Segments include synthesized oligonucleotides (custom or predefined), reagents & consumables, equipment and services (synthesis + purification + analytics).
• By application: Research (academic labs, molecular biology), diagnostics (PCR primers, probes, NGS prep) and therapeutics (ASOs, siRNAs, aptamers).
• By end-user: Academic & research institutes, pharmaceutical & biotechnology companies, diagnostic laboratories, CDMOs/CROs.
• Key players: Companies such as Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., Eurofins Genomics, Integrated DNA Technologies, Inc., and others figure prominently.

Key Insights

• Research tools remain a large volume segment, but therapeutic-grade oligonucleotides (high purity, GMP, large scale) are high-value and growing faster.
• The push toward automation, throughput and complexity (longer sequences, multiple modifications) is a major competitive differentiator.
• Regional diversification matters: North America dominates today, but Asia-Pacific is gaining share—and companies are expanding manufacturing footprints accordingly.

Regional Analysis

North America

North America (especially the U.S.) remains the largest regional market for oligonucleotide synthesis due to strong biotech/pharma infrastructure, high R&D investment and established CDMO networks

Europe

Europe has solid academic and industrial R&D pipelines for oligonucleotides (both therapeutics and diagnostics). Regulatory environment, funding frameworks and biotech ecosystems support growth, though perhaps at slightly slower pace than Asia-Pacific.

Asia-Pacific

This is the fastest-growing region in many analyses, with growth driven by China, India, Japan and South Korea’s increased biotech investment, localisation of manufacturing and demand for diagnostics.  

Latin America & Middle East & Africa (MEA)

These regions currently represent smaller market shares, but present opportunity given rising diagnostics and biotech capabilities. Investments in manufactur­ing infrastructure, diagnostics access, and regional supply-chain localisation may enhance growth over the next decade.

Technology Drivers & Opportunities

• Automation & AI for oligo design and synthesis: Use of robotics, AI algorithms for sequence optimisation, and high-throughput platforms allow faster turnaround and customisation at scale.
• Longer and more complex oligonucleotides: As research and therapies demand longer DNA/RNA strands with modifications (e.g., locked nucleic acids, morpholinos, aptamers), synthesis providers must adapt.
• Therapeutics & personalized medicine: With more antisense therapies, siRNA drugs and gene-editing platforms entering clinical phases, demand for high-grade oligos is rising.
• Diagnostics & genomics: PCR primers, probes, sequencing libraries and NGS-related oligo products form core demand drivers.
• Regional manufacturing and supply chain resilience: There is opportunity for companies to establish or localise manufacturing in emerging regions (Asia-Pacific, MEA) to capture growth and serve regional demand.
• Sustainability and green chemistry: Emerging methods (enzymatic synthesis, fewer hazardous reagents) are being developed to streamline synthesis and reduce waste.

Challenges & Barriers

• Cost and complexity of synthesis: Synthesis of long, high-fidelity oligonucleotides with modifications remains expensive and technically demanding.
• Quality control and regulatory compliance: For therapeutic use especially, manufacturers must meet stringent purity, impurity-profile, process validation and regulatory standards (GMP).
• Scale-up for commercial‐scale therapeutic oligos: Moving from research scale to commercial volumes (plus stringent specifications) is non-trivial.
• Supply-chain and reagent constraints: Dependence on certain chemistries, specialised reagents, and localisation of manufacturing can create risk.
• Technological disruption and competition: As new platforms (e.g., enzymatic synthesis) emerge, legacy providers must adapt or risk obsolescence.
• Global regulatory and IP environment: Different jurisdictions have varying rules for oligo therapeutics; intellectual property for sequences/modifications can be complex.

Future Outlook (2025–2030)

• The oligonucleotide synthesis market is poised to continue robust growth through 2030
• Therapeutic oligonucleotides will increasingly dominate value share (rather than bulk research oligos) as more drugs enter commercialization and demand shifts to GMP grade.
• Synthesis platforms will become more automated, flexible and integrated with analytics—leading to faster turnaround, customisation and lower cost.
• Regional manufacturing will broaden, with more facilities in Asia-Pacific and other emerging regions to meet local and global demand.
• Sustainability will gain more attention: greener synthesis approaches, reduction of hazardous waste, and more efficient reagent use will become differentiators.
• Providers that offer end-to-end services (design → synthesis → purification → analytics) will gain competitive advantage especially in therapeutic/diagnostic segments.
• As sequence complexity rises (e.g., longer synthetic genes, donor templates for gene editing), synthesis firms will need to innovate to stay ahead.
• The convergence of oligonucleotide synthesis with gene-editing, cell/gene therapy, personalized diagnostics and synthetic biology means that device suppliers, CDMOs, and biotech firms must view oligo capability as a strategic asset.

Business Opportunities

For companies in reagents/equipment manufacturing, CDMOs, diagnostics, and biotech service providers, here are actionable opportunities:

• Custom synthesis services: Offer high-fidelity custom oligo synthesis, purification, modification services (GMP grade) targeted at therapeutic/diagnostic applications.
• Automation & platform development: Develop and supply automated synthesizers, robotics, software/AI tools for oligo design and production—especially targeted at high throughput or long strand production.
• Regional manufacturing and service expansion: Consider establishing manufacturing or distribution footprint in fast-growing regions (Asia-Pacific, India, China) to capture local demand and cost advantages.
• Value-added analytics and QC services: Offer purification, quality control, impurity profiling, analytics (LC-MS, capillary electrophoresis) as part of a full solution.
• Sustainability-focused solutions: Innovate in greener chemistries, enzymatic synthesis, waste-minimisation—position this as a competitive differentiator.
• Partnerships with biotech/therapeutic developers: Form alliances with companies developing oligo-based therapies (antisense, siRNA, gene editing) to supply trustworthy synthesis capacity and secure early agreements.
• Diagnostic/Genomics supplier integration: Provide oligonucleotides for diagnostics (PCR primers, probes, NGS libraries) and partner with genomics/diagnostic firms to become preferred vendor.
• Training and consulting: As oligo synthesis becomes more complex (modifications, long strands, therapeutics grade), there is demand for expertise/training, process transfer and scale-up consulting.

Key Takeaways

• The oligonucleotide synthesis market is trending strongly in 2025, driven by therapeutic demand (antisense/siRNA), diagnostics/genomics growth, and advances in synthesis technology.
• Key segment shifts: from research-only oligos to high-value therapeutic/diagnostic oligos, from short sequences to longer/more complex ones, and from manual workflows to automated, high-throughput platforms.
• Regions: North America leads today; Asia-Pacific is the fastest growing; Europe remains an innovation hub; emerging markets hold future potential.
• Technology and manufacturing drivers: automation/AI, longer and modified oligos, sustainability, regional manufacturing expansion, integration with downstream therapeutic/diagnostic pipelines.
• Barriers exist—cost, complexity, scale-up, regulatory/quality demands—but they are manageable with strategic investment and capability building.
• For companies, there is a clear opportunity to position in the value chain—whether in equipment, reagents, synthesis services, analytics or regional expansion—to capitalise on the oligonucleotide synthesis wave.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=200829350